Please login to the form below

Not currently logged in
Email:
Password:

anti-PD-1

This page shows the latest anti-PD-1 news and features for those working in and with pharma, biotech and healthcare.

AZ’s MYSTIC survival data is in – and it’s a bust

AZ’s MYSTIC survival data is in – and it’s a bust

There’s no doubt that overall the study is a big disappointment, and will allow Merck &Co’s rival PD-1 inhibitor Keytruda (pembrolizumab) to maintain its fierce grip on the ... We are encouraged to see that Imfinzi monotherapy activity is in-line

Latest news

  • Keytruda hits survival targets in first-line kidney cancer Keytruda hits survival targets in first-line kidney cancer

    MSD says Keytruda is the first anti-PD-1 drug to improve both OS and PFS in first-line RCC, and that throws down a gauntlet to Merck and its partner ... Pfizer when it presents the JAVELIN Renal 101 study of its PD-1 drug Bavencio (avelumab) plus Inlyta

  • New leader at Medivir after setbacks New leader at Medivir after setbacks

    The HDAC inhibitor class has taken a knock recently, however, after Syndax’s rival entinostat candidate failed to hit the mark in a combination trial with Merck &Co/MSD’s ... PD-1 drug Keytruda (pembrolizumab) in lung cancer.

  • FDA green lights BMS’ Opdivo for ‘hard-to-treat’ small cell lung cancer FDA green lights BMS’ Opdivo for ‘hard-to-treat’ small cell lung cancer

    However, treating the disease from a ‘different angle’, Opdivo can target and block the activity of PD-1, a protein that prevents T cells from recognising and attacking inflamed tissues and ... It’s a significant win for BMS, which is chasing rival

  • Keytruda is first I-O drug cleared for melanoma in China Keytruda is first I-O drug cleared for melanoma in China

    It’s not the first PD-1 inhibitor to get a green light in China, however, as Bristol-Myers Squibb pipped it to the post when it won approval for Opdivo ... Meanwhile, Hengrui Medicine also has an anti-PD-1 drug in registration trials, and there are

  • China’s BeiGene takes PD-1 antibody into pivotal trials China’s BeiGene takes PD-1 antibody into pivotal trials

    The PD-1/PD-L1 category has been transforming cancer treatment in Western markets, but so far just one of the five approved drugs have been launched in the big Chinese ... Along with BeiGene, Hengrui Medicine also has an anti-PD-1 drug in registration

More from news
Approximately 3 fully matching, plus 48 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    Gilead has been trying to diversify away from anti-viral therapies into oncology and Kite is a good fit with its CAR-T technology and a lead product in priority review ... Licence to develop and commercialise. GLS-010, anti-PD-1 antibody in phase I for

  • The new launch paradigm The new launch paradigm

    Thousands of patients worldwide are in clinical trials with anti-PD-1 or anti-PD-L1 drugs produced by several pharmaceutical companies prior to the expected arrival of this new exciting

  • Deal Watch July 2016 Deal Watch July 2016

    At the other end of the development spectrum Servier paid the same amount upfront for the rights to Sorrento's immuno-oncology product: STI-A1110, an anti-PD-1 mAb, presently ... Acquisition. 1, 530. AstraZeneca/ Leo Pharma. Tralokinumab (anti-IL-13) in

  • Deal Watch October 2015 Deal Watch October 2015

    Up to 3 anti-PD-1 based bispecific antibodies for oncology. Expansion of existing collaboration. ... Research collaboration, licence. 535. XOMA Corporation/ Novartis. Anti-transforming growth factor-beta (TGFb) antibody programme incl XOMA089 plus other

  • Pharma deals in September 2015 Pharma deals in September 2015

    Agenus will invest the proceeds in its growing pipeline of pre-clinical immuno-oncology treatments which include a series of PD-1 and CTLA-4 inhibitor programmes. ... Acquisition - company. 1, 230. Jiangsu Hengrui Medicine. Incyte. anti-PD-1, checkpoint

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics